ReviewFrontiers in oncology2023
Traditional Chinese medicine inhibits PD-1/PD-L1 axis to sensitize cancer immunotherapy: a literature review.
Review in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effects of moxibustion therapies on immune function in cancer animal models: a systematic review and meta-analysis.Frontiers in immunology · 2026Pooled it
- Chinese Medicine in Colorectal Cancer Treatment: From Potential Targets and Mechanisms to Clinical Application.Chinese journal of integrative medicine · 2026Review
- Natural Products Targeting Key Molecular Hallmarks in Gastric Cancer: Focus on Apoptosis, Inflammation, and Chemoresistance.International journal of molecular sciences · 2026Review
- Immune-excluded and immune-suppressive tumor microenvironments: mechanisms, spatial biomarkers, and therapeutic rewiring.Frontiers in oncology · 2026Review
- Gut microbiota-regulated cell death: a review on pyroptosis, ferroptosis, and related mechanisms.Frontiers in microbiology · 2026Review
- Astragalus polysaccharide antagonized anti PD-1 efficacy in melanoma through inhibiting JAK-STAT1/CIITA and TLR/NF-κB signaling.Frontiers in immunology · 2026Article
- The Role of Jianpi Jiedu Recipe in Modulating the CRC Microenvironment.Combinatorial chemistry & high throughput screening · 2026Article
- Isorhamnetin inhibits migration and promotes apoptosis via modulation of oxidative stress, mitochondrial dysfunction, and the TIGIT/CD155 axis in 4T1 breast cancer cells.Frontiers in cell and developmental biology · 2026Article
- Cardioprotective effect of acupuncture in mice with diabetic cardiomyopathy by alleviating cardiac fibrosis and apoptosis.American journal of cardiovascular disease · 2026Article
- Mechanism of action ofOncology letters · 2025Article
- Unveiling the power of plumbagin: revitalizing exhausted T cells to combat tongue cancer.Cancer cell international · 2025Article
- The tumor microenvironment in hepatocellular carcinoma: mechanistic insights and therapeutic potential of traditional Chinese medicine.Molecular cancer · 2025Review
- Regulatory effects of traditional Chinese medicine on the breast-cancer immune microenvironment.Frontiers in immunology · 2025Review
- Revisiting of Cancer Immunotherapy: Insight from the Dialogue between Glycolysis and PD-1/PD-L1 Axis in the Tumor Microenvironment.International journal of biological sciences · 2025Review
- A bibliometric and visualization analysis of the role of traditional Chinese medicine in cancer immunotherapy.Frontiers in immunology · 2025Article
- Harnessing the Power of Traditional Chinese Medicine in Cancer Treatment: The Role of Nanocarriers.International journal of nanomedicine · 2025Review
- Molecular insight into binding affinities and blockade effects of selected flavonoid compounds on the PD-1/PD-L1 pathway.RSC advances · 2024Article
- Herb pair of Huangqi-Danggui exerts anti-tumor immunity to breast cancer by upregulating PIK3R1.Animal models and experimental medicine · 2024Article
- Integrative Oncology Approaches to Supporting Immune Checkpoint Inhibitor Treatment of Solid Tumours.Current oncology reports · 2024Review
- Rhus Verniciflua Stokes Inhibits PD-1 Expression and Induces Anticancer Effects by Enhancing T Cell Function.Integrative cancer therapiesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Programmed death-1 (PD-1) and its programmed death-ligand 1 (PD-L1) comprise the PD-1/PD-L1 axis and maintain tumor immune evasion. Cancer immunotherapy based on anti-PD-1/PD-L1 antibodies is the most promising anti-tumor treatment available but is currently facing the thorny problem of unsatisfactory outcomes. Traditional Chinese Medicine (TCM), with its rich heritage of Chinese medicine monomers, herbal formulas, and physical therapies like acupuncture, moxibustion, and catgut implantation, is a multi-component and multi-target system of medicine known for enhancing immunity and preventing the spread of disease. TCM is often used as an adjuvant therapy for cancer in clinical practices, and recent studies have demonstrated the synergistic effects of combining TCM with cancer immunotherapy. In this review, we examined the PD-1/PD-L1 axis and its role in tumor immune escape while exploring how TCM therapies can modulate the PD-1/PD-L1 axis to improve the efficacy of cancer immunotherapy. Our findings suggest that TCM therapy can enhance cancer immunotherapy by reducing the expression of PD-1 and PD-L1, regulating T-cell function, improving the tumor immune microenvironment, and regulating intestinal flora. We hope this review may serve as a valuable resource for future studies on the sensitization of immune checkpoint inhibitors (ICIs) therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.